Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.55), $0.07 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $73 million versus the consensus estimate of $79.8 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.